Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2009 Dec 11;2(3):234-241.
doi: 10.1159/000260901.

Final Report of the First Refractory Germ Cell Tumor Treated with Sunitinib Malate

Joan Manel Gasent Blesa  1 , Enrique Grande Pulido, Juan Laforga Canales, Vicente Alberola Candel
Affiliations
Case Reports

Final Report of the First Refractory Germ Cell Tumor Treated with Sunitinib Malate

Joan Manel Gasent Blesa et al. Case Rep Oncol. .

Abstract

Patients with advanced germ cell tumors can be cured with cisplatin-based chemotherapy, but the outcome remains unsatisfactory for patients with relapsed disease, including those patients with refractory disease after bone marrow transplantation. Targeted therapies have changed the standard of care for many advanced solid tumors. We have identified, in the literature, potential targets for the treatment of refractory germ cell tumors, and applied to a patient with a refractory disease. We chose sunitinib for this purpose. To our knowledge, this is the first case to be treated with sunitinib, and we have found a promising activity.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Evolution of the HCG level.
Fig. 2
Fig. 2
Upper panel: CT scan May 2008. Lower panel: CT scan July 2008.
See this image and copyright information in PMC

References

    1. Arora A, Scholar EM. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther. 2005;315:971–979. - PubMed
    1. Pawson T. Regulation and targets of receptor tyrosine kinases. Eur J Cancer. 2002;38:S3–S10. - PubMed
    1. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/ pharmacodynamic relationship. Clin Cancer Res. 2003;9:327–337. - PubMed
    1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57–70. - PubMed
    1. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9:669–676. - PubMed

Publication types